An observational study in Colorectal Cancer Metastatic, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.
Sponsored by Memorial Sloan Kettering Cancer Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Colorectal Neoplasms by Memorial Sloan Kettering Cancer Center — 12 open to participants now, 18 under way, none of them phase 3. Colorectal Neoplasms · Memorial Sloan Kettering Cancer Center.
Among the 69 studies in Colorectal Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the 8th largest by enrollment of the 21 observational ones that give a count, is one of 2 that started in 2017, is one of 21 observational ones, reaches primary completion later than 3 of the 17 other live ones, and was the 52nd registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →12 of the 69 studies in Colorectal Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 6 countries. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States, Ghana, South Africa and 1 more country
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States, Mexico
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States, Nigeria
Ages 18+
By country, each count listing its studies:
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 25 · Phase 3 2
First in 1981; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 169 is below the median of 250 across 1,444 observational studies indexed under Colorectal Neoplasms.
Median enrollment 35 across the 35 interventional studies, 110 across the 21 observational. Of the 50 that completed or were terminated, 9 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 325 are open to participants now.
Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.
12 of the studies in Colorectal Neoplasms by Memorial Sloan Kettering Cancer Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06130280Memorial Sloan Kettering Cancer CenterA Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer | 2026-11 |
| NCT00335816Memorial Sloan Kettering Cancer CenterRadiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer | 2026-12 |
| NCT04668872Memorial Sloan Kettering Cancer CenterBiopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation | 2026-12-07 |
| NCT03038568Memorial Sloan Kettering Cancer CenterAssessing How Normal Variations in CT Scanning Affects Its Interpretation | 2027-01-27 |
| NCT04812912Memorial Sloan Kettering Cancer CenterChanges in Reproductive and Sexual Health in People With Early Onset Colorectal Cancer | 2027-03-18 |
Add all 12 to your calendar (.ics) → With an account.
Among the 69 studies in Colorectal Neoplasms by Memorial Sloan Kettering Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to see how measurements of tumor differences vary with slight changes in CT scan parameters. Reproducible radiomic features can be extracted for abdominal tumors, and specifically colorectal liver metastases, imaged with clinical CT scanners even in the setting of variable scan parameters and variable contrast timing. Participants will be consented to undergo an additional CT of their abdomen.
Patients who undergo contrast enhanced CT scanning for colorectal liver metastases will be consented for one additional CT abdomen phase during the same imaging session.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
-15 second time gap between routine abdominal CT and add on CT, Noise Index of 12
Diagnostic Test: CT scan
-15 second time gap between routine abdominal CT and add on CT, Noise Index of 14
Diagnostic Test: CT scan
-15 second time gap between routine abdominal CT and add on CT, Noise Index of 16
Diagnostic Test: CT scan
-10 second time gap between routine abdominal CT and add on CT, Noise index 12
Diagnostic Test: CT scan
-10 second time gap between routine abdominal CT and add on CT, Noise index 14
Diagnostic Test: CT scan
-10 second time gap between routine abdominal CT and add on CT, Noise index 16
Diagnostic Test: CT scan
\- 5 second time gap between routine abdominal CT and add on CT, Noise index 12
Diagnostic Test: CT scan
\- 5 second time gap between routine abdominal CT and add on CT, Noise index 14
Diagnostic Test: CT scan
\- 5 second time gap between routine abdominal CT and add on CT, Noise index 16
Diagnostic Test: CT scan
\+ 5 second time gap between routine abdominal CT and add on CT, Noise index 12
Diagnostic Test: CT scan
\+ 5 second time gap between routine abdominal CT and add on CT, Noise index 14
Diagnostic Test: CT scan
\+ 5 second time gap between routine abdominal CT and add on CT, Noise index 16
Diagnostic Test: CT scan
\+ 10 second time gap between routine abdominal CT and add on CT, Noise index 12
Diagnostic Test: CT scan
\+ 10 second time gap between routine abdominal CT and add on CT, Noise index 14
Diagnostic Test: CT scan
\+ 10 second time gap between routine abdominal CT and add on CT, Noise index 16
Diagnostic Test: CT scan
\+ 15 second time gap between routine abdominal CT and add on CT, Noise 12
Diagnostic Test: CT scan
\+ 15 second time gap between routine abdominal CT and add on CT, Noise 14
Diagnostic Test: CT scan
\+ 15 second time gap between routine abdominal CT and add on CT, Noise 16
Diagnostic Test: CT scan
Patients with colorectal liver metastases scheduled for abdominopelvic CECT will be consented to undergo an additional CT of their abdomen (termed add-on CT) within 15 seconds, before or after, their clinical portal venous phase CT (PV CT), which is performed at a fixed delay of 80 seconds at our institution.
assess the stability (reproducibility) of radiomic measurements obtained from repeat abdominal CT scans
There will be 18 cohorts, each cohort differing by the length of the time gap in acquisition and noise index. In addition each acquisition will be reconstructed in 21 different ways (combinations of 3 slice thicknesses and 7 ASiR levels).
Time frame: 2 years
PDFs hosted by the registry, ClinicalTrials.gov.
Started Jan 2017 (actual). Primary completion is estimated for Jan 2027, 120 months after the start.
Of 531 non-industry observational studies under Colorectal Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 132. This study's planned 120 months is above that.
Counting every sponsor, half of 648 studies reached it within 52 months; a quarter within 27 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Memorial Sloan Kettering Cancer Center →